MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers | Zendy

Livingstone Fultang | Zendy; Silvia Panetti | Zendy; Margaret H.L. Ng | Zendy; Paul J. Collins | Zendy; Suzanne Graef | Zendy; Nagy Rizkalla | Zendy; Sarah Booth | Zendy; Richard Lenton | Zendy; Boris Noyvert | Zendy; Claire ShanLowe | Zendy; Gary Middleton | Zendy; Francis Mussai | Zendy; Carmela De Santo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers

Author(s) -

Livingstone Fultang,

Silvia Panetti,

Margaret H.L. Ng,

Paul J. Collins,

Suzanne Graef,

Nagy Rizkalla,

Sarah Booth,

Richard Lenton,

Boris Noyvert,

Claire ShanLowe,

Gary Middleton,

Francis Mussai,

Carmela De Santo

Publication year - 2019

Publication title -

ebiomedicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.596

H-Index - 63

ISSN - 2352-3964

DOI - 10.1016/j.ebiom.2019.08.025

Subject(s) - gemtuzumab ozogamicin , immunotherapy , medicine , immunity , cancer research , immunology , immune system , cd33 , biology , stem cell , cd34 , genetics

Targeting of MDSCs is a major clinical challenge in the era of immunotherapy. Antibodies which deplete MDSCs in murine models can reactivate T cell responses. In humans such approaches have not developed due to difficulties in identifying targets amenable to clinical translation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research